By Christian Moess Laursen
Argent BioPharma said it plans to leave the London Stock Exchange while mulling a listing in the U.S.
The pharmaceutical company, which will keep its stock-market listing in Australia, said it has taken steps to cancel the admission of its shares on the LSE.
The decision followed a review of both the listing requirements and costs associated with the transfer of all its ordinary shares, it said Friday.
Argent Biopharma expects the last day of trading on the LSE to be Dec. 31.
The company said it might still look to explore opportunities to expand its accessibility to investors, including a potential listing on an U.S. exchange.
The company's main operations and management are based in the EU, with a growing investor base in the U.S.
Write to Christian Moess Laursen at christian.moess@wsj.com
(END) Dow Jones Newswires
November 29, 2024 02:57 ET (07:57 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。